Hormonal treatment in nonmalignant gynaecological conditions

M. S. Marsh
In: MRCOG Part One · 2015 · pp. 413–422 · doi:10.1017/cbo9781107587519.028 · W2557110104
book-chapter OA: closed CC0
View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper reviews the use of hormonal treatments for nonmalignant gynecological conditions, discussing their mechanisms and clinical applications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

This chapter reviews hormonal treatment approaches for nonmalignant gynaecological conditions, summarizing relevant pharmacologic evidence and key considerations for hormone use. It covers foundational background and references major trial and systematic review literature on hormone effects in areas such as endometrium (including risks of endometrial hyperplasia and changes in histology) and outcomes associated with estrogen/progestin therapy, while also noting that the evidence base includes randomized trials and meta-analyses. A major limitation explicitly reflected by the chapter format is that it provides a high-level educational synthesis rather than presenting original patient-level methods or outcomes. Relevance to endometriosis: endometriosis is mentioned through cited evidence on oral contraceptives for pain associated with endometriosis and broader “drug treatment of endometriosis,” though the chapter’s main focus is hormonal treatment in nonmalignant gynaecological conditions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK